Bristol Cup Posters
Identifieur interne : 001577 ( Main/Exploration ); précédent : 001576; suivant : 001578Bristol Cup Posters
Auteurs :Source :
- British Journal of Dermatology [ 0007-0963 ] ; 2011-07.
English descriptors
- Teeft :
- Abnormality, Abscess, Acad, Acad dermatol, Acne, Acral, Acral lesions, Adalimumab, Adverse effects, Adverse events, Aetiology, Alitretinoin, Allergy, Alloknesis, Alopecia, Alopecia areata, Antibiotic, Aqueous cream, Arch dermatol, Atopic, Atopic dermatitis, Atypical, Aureus, Badbir, Baseline, Beacon group, Belfast, Bexarotene, Bexarotene therapy, Biliary, Biliary sepsis, Biologics, Biopsy, Biopsy tract, Bone mineral density, Breslow, Breslow depth, Briakinumab, Bristol, British association, Bullosa, Carcinoma, Cardiff, Case report, Case reports, Case series, Centre, Chemotherapy, Chronic biliary obstruction, Chronic plaque psoriasis, Ciclosporin, Clinic, Clinical examination, Clinical features, Clinical meeting, Clinical meetings, Clinical practice, Clinical response, Clinical trials, Clinician, Cohort, Consecutive patients, Control group, Cork university hospital, Cowpox, Cowpox infection, Current practice, Cutaneous, Cutaneous disease, Cutaneous features, Cutaneous manifestations, Cutaneous melanoma, Cutaneous symptoms, Database, Dermal, Dermatitis, Dermatol, Dermatological, Dermatological manifestations, Dermatologist, Dermatologists british journal, Dermatology, Dermatology centre, Dermatology department, Dermatology transplant clinic, Dermatomyositis, Diphencyprone, Distress syndrome, Dos, Ectropion, Eczema, Edinburgh, Effective treatment, Epidermolysis, Epidermolysis bullosa, Erythema, Erythema migrans, Erythematosus, Erythrodermic psoriasis, Ester, Excision, Facial, Family members, Female patients, Foreign travel, Foundation trust, Fumaric, Fumaric acid esters, Gangrenosum, General population, General practitioner, Generalized vitiligo, Glucocorticoid, Graft, Guideline, Gvhd, Hair kinking, Hair loss, Half days, Healthcare, Healthcare professionals, Healthcare workers, High rate, Histiocytosis, Histology, Hydroxychloroquine, Imiquimod, Immunosuppressed, Immunosuppressed patients, Intravenous, Intravenous immunoglobulin, Isotretinoin, Juvenile dermatomyositis, Keloid, Kinking, Langerhans, Langerhans cell histiocytosis, Large teaching hospital, Lasik, Lesion, Lipid, Livedoid vasculopathy, Local toxicity, Localized, Longitudinal placement, Lower legs, Lupus, Lyme disease, Lymphoma, Male patients, Malignancy, Malignant, Malignant melanoma, Many patients, Media coverage, Median, Median number, Medical education, Medical history, Medication, Melanocyte, Melanoma, Methotrexate, Mofetil, Molecular medicine, Mtxpg3 concentration, Multiple lesions, Mutation, Mycophenolate, Mycophenolate mofetil, Mycosis fungoides, Myeloid, Myeloid sarcoma, Ndings, Neuropathic pruritus, Nodule, Northern ireland, Norwich, Novel approach, Oilatum, Ongoing, Oral prednisolone, Outpatient, Paediatric, Papule, Pasi, Pathogenesis, Pcos, Pharmacological treatment, Phenotype, Phototherapy, Placebo, Plaque, Poster, Potential risk, Prednisolone, Previous studies, Primary care, Programme, Progressive kinking, Prospective study, Pruritus, Psoriasis, Psoriasis area, Public awareness, Punch biopsy, Pyoderma, Pyoderma gangrenosum, Radiotherapy, Randomized, Range years, Rash, Recurrence, Referral, Regimen, Regrowth, Renal, Renal failure, Renal transplant, Renal transplant patients, Renal transplantation, Respiratory failure, Responder, Response rate, Response rates, Retreatment, Retrospective, Retrospective study, Rituximab, Roche, Roche brand, Roche group, Rosacea, Royal college, Salford, Sarcoma, Scarring, Seasonal variation, Sebum, Sebutape, Secondary care, Sepsis, Serious infections, Several months, Several years, Severe acne, Severe psoriasis, Severity index, Skin biopsy, Skin cancer, Skin cancer awareness, Skin disease, Skin graft, Skin infection, Skin lesions, Socs3, Socs3 gene expression, Squamous cell carcinoma, Stable vitiligo lesions, Steroid, Suppl, Surgical, Surgical debridement, Surgical excision, Surgical procedures, Sweet syndrome, Syndrome, Syphilis, Systemic, Systemic lupus erythematosus, Systemic symptoms, Systemic therapy, Teledermoscopy, Teledermoscopy model, Testosterone, Thalidomide, Therapeutic options, Topical, Topical imiquimod, Topical testosterone, Total cholesterol, Trainee, Transplant, Transplant patients, Transplantation, Tumour, Tumour necrosis factor, Tunga penetrans, Ulceration, University hospital, Upper arms, Vasculitis, Vasculopathy, Vitiligo, White woman, Whole blood, Young adults.
Url:
DOI: 10.1111/j.1365-2133.2011.10277.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002385
- to stream Istex, to step Curation: 002385
- to stream Istex, to step Checkpoint: 000553
- to stream Main, to step Merge: 001579
- to stream Main, to step Curation: 001577
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bristol Cup Posters</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:715C0A559B50A8FE9E76AFA8ACA0294D0F6F6707</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1111/j.1365-2133.2011.10277.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-1TJ69CTG-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002385</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002385</idno>
<idno type="wicri:Area/Istex/Curation">002385</idno>
<idno type="wicri:Area/Istex/Checkpoint">000553</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000553</idno>
<idno type="wicri:Area/Main/Merge">001579</idno>
<idno type="wicri:Area/Main/Curation">001577</idno>
<idno type="wicri:Area/Main/Exploration">001577</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Bristol Cup Posters</title>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">British Journal of Dermatology</title>
<title level="j" type="sub">Abstracts for the British Association of Dermatologists 91st Annual Meeting, 5‐7 July 2011, London, UK</title>
<title level="j" type="alt">BRITISH JOURNAL OF DERMATOLOGY</title>
<idno type="ISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<imprint><biblScope unit="vol">165</biblScope>
<biblScope unit="issue">s1</biblScope>
<biblScope unit="page" from="20">20</biblScope>
<biblScope unit="page" to="62">62</biblScope>
<biblScope unit="page-count">43</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2011-07">2011-07</date>
</imprint>
<idno type="ISSN">0007-0963</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0007-0963</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abnormality</term>
<term>Abscess</term>
<term>Acad</term>
<term>Acad dermatol</term>
<term>Acne</term>
<term>Acral</term>
<term>Acral lesions</term>
<term>Adalimumab</term>
<term>Adverse effects</term>
<term>Adverse events</term>
<term>Aetiology</term>
<term>Alitretinoin</term>
<term>Allergy</term>
<term>Alloknesis</term>
<term>Alopecia</term>
<term>Alopecia areata</term>
<term>Antibiotic</term>
<term>Aqueous cream</term>
<term>Arch dermatol</term>
<term>Atopic</term>
<term>Atopic dermatitis</term>
<term>Atypical</term>
<term>Aureus</term>
<term>Badbir</term>
<term>Baseline</term>
<term>Beacon group</term>
<term>Belfast</term>
<term>Bexarotene</term>
<term>Bexarotene therapy</term>
<term>Biliary</term>
<term>Biliary sepsis</term>
<term>Biologics</term>
<term>Biopsy</term>
<term>Biopsy tract</term>
<term>Bone mineral density</term>
<term>Breslow</term>
<term>Breslow depth</term>
<term>Briakinumab</term>
<term>Bristol</term>
<term>British association</term>
<term>Bullosa</term>
<term>Carcinoma</term>
<term>Cardiff</term>
<term>Case report</term>
<term>Case reports</term>
<term>Case series</term>
<term>Centre</term>
<term>Chemotherapy</term>
<term>Chronic biliary obstruction</term>
<term>Chronic plaque psoriasis</term>
<term>Ciclosporin</term>
<term>Clinic</term>
<term>Clinical examination</term>
<term>Clinical features</term>
<term>Clinical meeting</term>
<term>Clinical meetings</term>
<term>Clinical practice</term>
<term>Clinical response</term>
<term>Clinical trials</term>
<term>Clinician</term>
<term>Cohort</term>
<term>Consecutive patients</term>
<term>Control group</term>
<term>Cork university hospital</term>
<term>Cowpox</term>
<term>Cowpox infection</term>
<term>Current practice</term>
<term>Cutaneous</term>
<term>Cutaneous disease</term>
<term>Cutaneous features</term>
<term>Cutaneous manifestations</term>
<term>Cutaneous melanoma</term>
<term>Cutaneous symptoms</term>
<term>Database</term>
<term>Dermal</term>
<term>Dermatitis</term>
<term>Dermatol</term>
<term>Dermatological</term>
<term>Dermatological manifestations</term>
<term>Dermatologist</term>
<term>Dermatologists british journal</term>
<term>Dermatology</term>
<term>Dermatology centre</term>
<term>Dermatology department</term>
<term>Dermatology transplant clinic</term>
<term>Dermatomyositis</term>
<term>Diphencyprone</term>
<term>Distress syndrome</term>
<term>Dos</term>
<term>Ectropion</term>
<term>Eczema</term>
<term>Edinburgh</term>
<term>Effective treatment</term>
<term>Epidermolysis</term>
<term>Epidermolysis bullosa</term>
<term>Erythema</term>
<term>Erythema migrans</term>
<term>Erythematosus</term>
<term>Erythrodermic psoriasis</term>
<term>Ester</term>
<term>Excision</term>
<term>Facial</term>
<term>Family members</term>
<term>Female patients</term>
<term>Foreign travel</term>
<term>Foundation trust</term>
<term>Fumaric</term>
<term>Fumaric acid esters</term>
<term>Gangrenosum</term>
<term>General population</term>
<term>General practitioner</term>
<term>Generalized vitiligo</term>
<term>Glucocorticoid</term>
<term>Graft</term>
<term>Guideline</term>
<term>Gvhd</term>
<term>Hair kinking</term>
<term>Hair loss</term>
<term>Half days</term>
<term>Healthcare</term>
<term>Healthcare professionals</term>
<term>Healthcare workers</term>
<term>High rate</term>
<term>Histiocytosis</term>
<term>Histology</term>
<term>Hydroxychloroquine</term>
<term>Imiquimod</term>
<term>Immunosuppressed</term>
<term>Immunosuppressed patients</term>
<term>Intravenous</term>
<term>Intravenous immunoglobulin</term>
<term>Isotretinoin</term>
<term>Juvenile dermatomyositis</term>
<term>Keloid</term>
<term>Kinking</term>
<term>Langerhans</term>
<term>Langerhans cell histiocytosis</term>
<term>Large teaching hospital</term>
<term>Lasik</term>
<term>Lesion</term>
<term>Lipid</term>
<term>Livedoid vasculopathy</term>
<term>Local toxicity</term>
<term>Localized</term>
<term>Longitudinal placement</term>
<term>Lower legs</term>
<term>Lupus</term>
<term>Lyme disease</term>
<term>Lymphoma</term>
<term>Male patients</term>
<term>Malignancy</term>
<term>Malignant</term>
<term>Malignant melanoma</term>
<term>Many patients</term>
<term>Media coverage</term>
<term>Median</term>
<term>Median number</term>
<term>Medical education</term>
<term>Medical history</term>
<term>Medication</term>
<term>Melanocyte</term>
<term>Melanoma</term>
<term>Methotrexate</term>
<term>Mofetil</term>
<term>Molecular medicine</term>
<term>Mtxpg3 concentration</term>
<term>Multiple lesions</term>
<term>Mutation</term>
<term>Mycophenolate</term>
<term>Mycophenolate mofetil</term>
<term>Mycosis fungoides</term>
<term>Myeloid</term>
<term>Myeloid sarcoma</term>
<term>Ndings</term>
<term>Neuropathic pruritus</term>
<term>Nodule</term>
<term>Northern ireland</term>
<term>Norwich</term>
<term>Novel approach</term>
<term>Oilatum</term>
<term>Ongoing</term>
<term>Oral prednisolone</term>
<term>Outpatient</term>
<term>Paediatric</term>
<term>Papule</term>
<term>Pasi</term>
<term>Pathogenesis</term>
<term>Pcos</term>
<term>Pharmacological treatment</term>
<term>Phenotype</term>
<term>Phototherapy</term>
<term>Placebo</term>
<term>Plaque</term>
<term>Poster</term>
<term>Potential risk</term>
<term>Prednisolone</term>
<term>Previous studies</term>
<term>Primary care</term>
<term>Programme</term>
<term>Progressive kinking</term>
<term>Prospective study</term>
<term>Pruritus</term>
<term>Psoriasis</term>
<term>Psoriasis area</term>
<term>Public awareness</term>
<term>Punch biopsy</term>
<term>Pyoderma</term>
<term>Pyoderma gangrenosum</term>
<term>Radiotherapy</term>
<term>Randomized</term>
<term>Range years</term>
<term>Rash</term>
<term>Recurrence</term>
<term>Referral</term>
<term>Regimen</term>
<term>Regrowth</term>
<term>Renal</term>
<term>Renal failure</term>
<term>Renal transplant</term>
<term>Renal transplant patients</term>
<term>Renal transplantation</term>
<term>Respiratory failure</term>
<term>Responder</term>
<term>Response rate</term>
<term>Response rates</term>
<term>Retreatment</term>
<term>Retrospective</term>
<term>Retrospective study</term>
<term>Rituximab</term>
<term>Roche</term>
<term>Roche brand</term>
<term>Roche group</term>
<term>Rosacea</term>
<term>Royal college</term>
<term>Salford</term>
<term>Sarcoma</term>
<term>Scarring</term>
<term>Seasonal variation</term>
<term>Sebum</term>
<term>Sebutape</term>
<term>Secondary care</term>
<term>Sepsis</term>
<term>Serious infections</term>
<term>Several months</term>
<term>Several years</term>
<term>Severe acne</term>
<term>Severe psoriasis</term>
<term>Severity index</term>
<term>Skin biopsy</term>
<term>Skin cancer</term>
<term>Skin cancer awareness</term>
<term>Skin disease</term>
<term>Skin graft</term>
<term>Skin infection</term>
<term>Skin lesions</term>
<term>Socs3</term>
<term>Socs3 gene expression</term>
<term>Squamous cell carcinoma</term>
<term>Stable vitiligo lesions</term>
<term>Steroid</term>
<term>Suppl</term>
<term>Surgical</term>
<term>Surgical debridement</term>
<term>Surgical excision</term>
<term>Surgical procedures</term>
<term>Sweet syndrome</term>
<term>Syndrome</term>
<term>Syphilis</term>
<term>Systemic</term>
<term>Systemic lupus erythematosus</term>
<term>Systemic symptoms</term>
<term>Systemic therapy</term>
<term>Teledermoscopy</term>
<term>Teledermoscopy model</term>
<term>Testosterone</term>
<term>Thalidomide</term>
<term>Therapeutic options</term>
<term>Topical</term>
<term>Topical imiquimod</term>
<term>Topical testosterone</term>
<term>Total cholesterol</term>
<term>Trainee</term>
<term>Transplant</term>
<term>Transplant patients</term>
<term>Transplantation</term>
<term>Tumour</term>
<term>Tumour necrosis factor</term>
<term>Tunga penetrans</term>
<term>Ulceration</term>
<term>University hospital</term>
<term>Upper arms</term>
<term>Vasculitis</term>
<term>Vasculopathy</term>
<term>Vitiligo</term>
<term>White woman</term>
<term>Whole blood</term>
<term>Young adults</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001577 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001577 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:715C0A559B50A8FE9E76AFA8ACA0294D0F6F6707 |texte= Bristol Cup Posters }}
This area was generated with Dilib version V0.6.33. |